Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has reported a recent transaction by its Chief Financial Officer, Michael Burkes Brophy. According to the latest SEC filing, Brophy sold 1,523 shares of Natera common stock on April 23, 2024, at an average price of $91.3792 per share, totaling over $139,170.
The sale was part of a pre-arranged trading plan under Rule 10b5-1, which allows company insiders to sell stocks at predetermined times to avoid accusations of insider trading. This particular sale was conducted to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), as outlined in Brophy's stock unit agreements from previous years.
In the days leading up to the sale, Brophy also acquired additional shares of Natera stock through the vesting of RSUs. The transactions took place over three consecutive days, with Brophy receiving 1,521 shares on April 20, 1,145 shares on April 21, and 1,250 shares on April 22. These transactions did not involve any cash exchange as they were related to previously granted equity that had vested according to the company's standard vesting schedule.
Following the sale, Brophy's direct ownership in the company stands at 73,039 shares of common stock. Investors often monitor insider transactions for insights into how company executives perceive the value of their company stock. However, it's important to note that sales related to tax obligations can be a routine part of compensation for executives and may not necessarily signal a lack of confidence in the company.
Natera, based in Austin, Texas, specializes in genetic testing and has been expanding its portfolio of diagnostics services. The company's stock performance and executive transactions are closely watched by investors seeking to understand the health and future prospects of the genetics industry.
InvestingPro Insights
Natera, Inc. (NASDAQ:NTRA) has been making waves in the personalized genetic testing industry, and its financial metrics provide valuable insights for investors. With a market cap of $10.99 billion, Natera showcases significant presence in its sector. The company's revenue has seen a considerable uptick, with a revenue growth of 31.99% over the last twelve months as of Q4 2023, indicating a robust expansion in its business operations.
Investors tracking Natera's stock performance will find the price total return of 67.19% over the last year noteworthy, reflecting a strong market confidence in the company's growth trajectory. This aligns with one of the InvestingPro Tips that highlights Natera's high return over the same period. Moreover, the company's liquid assets have surpassed short-term obligations, demonstrating a solid financial footing that could reassure investors of its operational resilience.
While Natera operates with a moderate level of debt, analysts have expressed concerns regarding its profitability, as they do not anticipate the company will be profitable this year. This is further reflected in the adjusted P/E ratio of -25.98, suggesting that investors are valuing the company's growth prospects rather than current earnings. It's also important to note that Natera is trading at a high Price / Book multiple of 14.76, which could indicate that the stock is priced optimistically in relation to its book value.
For those interested in a deeper dive, there are additional InvestingPro Tips available for Natera, including the company's strong return over the last three months and the large price uptick over the last six months. To explore these insights and more, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. With this offer, investors can access a wealth of data and analysis to make informed decisions about their investments in the genetics industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.